IGM Biosciences (IGMS) Competitors $9.76 +0.23 (+2.41%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IGMS vs. CYRX, ZNTL, AUPH, XNCR, IDYA, CGON, NAMS, KROS, WVE, and AKROShould you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Cryoport (CYRX), Zentalis Pharmaceuticals (ZNTL), Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), IDEAYA Biosciences (IDYA), CG Oncology (CGON), NewAmsterdam Pharma (NAMS), Keros Therapeutics (KROS), Wave Life Sciences (WVE), and Akero Therapeutics (AKRO). IGM Biosciences vs. Cryoport Zentalis Pharmaceuticals Aurinia Pharmaceuticals Xencor IDEAYA Biosciences CG Oncology NewAmsterdam Pharma Keros Therapeutics Wave Life Sciences Akero Therapeutics IGM Biosciences (NASDAQ:IGMS) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking. Do insiders and institutionals have more ownership in IGMS or CYRX? 42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 92.9% of Cryoport shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by company insiders. Comparatively, 10.1% of Cryoport shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend IGMS or CYRX? IGM Biosciences presently has a consensus target price of $16.13, indicating a potential upside of 65.13%. Cryoport has a consensus target price of $12.50, indicating a potential upside of 90.26%. Given Cryoport's stronger consensus rating and higher probable upside, analysts plainly believe Cryoport is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38Cryoport 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer IGMS or CYRX? Cryoport received 170 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 64.96% of users gave Cryoport an outperform vote while only 50.35% of users gave IGM Biosciences an outperform vote. CompanyUnderperformOutperformIGM BiosciencesOutperform Votes7150.35% Underperform Votes7049.65% CryoportOutperform Votes24164.96% Underperform Votes13035.04% Is IGMS or CYRX more profitable? Cryoport has a net margin of -70.08% compared to IGM Biosciences' net margin of -7,534.03%. Cryoport's return on equity of -13.35% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-7,534.03% -155.42% -61.04% Cryoport -70.08%-13.35%-6.43% Which has higher valuation and earnings, IGMS or CYRX? Cryoport has higher revenue and earnings than IGM Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Cryoport, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.13M272.59-$246.42M-$3.64-2.68Cryoport$233.26M1.39-$99.59M-$3.38-1.94 Which has more volatility and risk, IGMS or CYRX? IGM Biosciences has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Does the media refer more to IGMS or CYRX? In the previous week, Cryoport had 1 more articles in the media than IGM Biosciences. MarketBeat recorded 3 mentions for Cryoport and 2 mentions for IGM Biosciences. Cryoport's average media sentiment score of 0.96 beat IGM Biosciences' score of 0.67 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IGM Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cryoport 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCryoport beats IGM Biosciences on 15 of the 18 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IGMS vs. The Competition Export to ExcelMetricIGM BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$567.29M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-2.684.8389.0213.30Price / Sales272.59372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book7.347.876.085.74Net Income-$246.42M$153.61M$119.07M$225.93M7 Day Performance-3.32%-2.00%-1.84%-1.32%1 Month Performance-37.68%-7.47%-3.65%0.60%1 Year Performance71.32%31.80%31.62%26.23% IGM Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IGMSIGM Biosciences4.7018 of 5 stars$9.77+2.4%$16.13+65.1%+63.3%$567.29M$2.13M-2.68190CYRXCryoport2.7225 of 5 stars$6.57-5.2%$12.50+90.3%-52.6%$342.80M$233.26M0.001,170Insider TradeZNTLZentalis Pharmaceuticals2.5838 of 5 stars$3.13+4.7%$10.00+219.5%-71.1%$213.08MN/A0.00160Analyst RevisionAUPHAurinia Pharmaceuticals1.6758 of 5 stars$8.24+1.4%$10.00+21.4%-10.8%$1.16B$175.51M0.00300XNCRXencor3.5459 of 5 stars$23.72+0.4%$35.75+50.7%+19.3%$1.65B$168.34M0.00280IDYAIDEAYA Biosciences4.1381 of 5 stars$25.54-1.2%$53.67+110.1%-17.1%$2.24B$23.39M0.0080Analyst ForecastCGONCG Oncology3.1617 of 5 stars$32.24-1.7%$63.88+98.1%N/A$2.22B$200,000.000.0061Short Interest ↓Analyst RevisionNAMSNewAmsterdam Pharma2.936 of 5 stars$20.01-15.5%$33.80+68.9%+110.6%$2.19B$14.09M0.0057Insider TradeNews CoverageGap DownHigh Trading VolumeKROSKeros Therapeutics3.4913 of 5 stars$54.14+1.0%$88.89+64.2%+80.5%$2.17B$150,000.000.00100WVEWave Life Sciences4.8489 of 5 stars$14.26+0.4%$21.89+53.5%+174.2%$2.17B$113.31M0.00240Analyst RevisionAKROAkero Therapeutics4.0502 of 5 stars$30.64-1.3%$46.83+52.9%+83.8%$2.14BN/A-8.1730Analyst ForecastInsider Trade Related Companies and Tools Related Companies CYRX Alternatives ZNTL Alternatives AUPH Alternatives XNCR Alternatives IDYA Alternatives CGON Alternatives NAMS Alternatives KROS Alternatives WVE Alternatives AKRO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IGMS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
